Fresenius Medical Care AG
No SEC Form 4 filings for $FMS in the last 30 days.
See all $FMS insider activity →Fresenius Medical Care AG reported interim results of its first tranche share buyback. From Aug 10 to Aug 14, 2026, it bought back 722,500 shares at weighted average prices around EUR 41.06 to EUR 42.36, totaling EUR 30.65m. A total of 5,151,274 shares have been acquired so far, via a commissioned credit institution.
Fresenius Medical Care (FMS) reported Q2 2026 revenue of EUR 4,861 million, up 5% organically, and adjusted operating income of EUR 569 million (+23% at constant currency). Adjusted basic EPS was EUR 1.13 (+28% constant currency). Management reaffirmed broadly flat 2026 revenue and operating income growth, citing U.S. referral execution issues and China regulatory headwinds.
Germany’s DAX rose modestly in Thursday morning trading, reaching 26,210.50 before easing to 26,169.49 (+0.12%). Deutsche Telekom gained about 6% on Q2 operating profit of €6.863bn and a larger 2026 buyback. Merck rose 1.5% after upgrading full-year guidance. Other moves included Henkel (+4.3%) and Siemens (-6%).
Over the past 7 days, alphai's AI scored 1 news story mentioning FMS (Fresenius Medical Care AG). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent FMS coverage spans earnings, market movers and corporate actions.
The update is a routine buyback tranche disclosure, likely supportive at the margin but not a major fundamental reset.
Operational execution improved via Care Delivery margin expansion and transformation savings, but U.S. referral capture and China regulatory headwinds remain drags.
Price action suggests earnings-related optimism, but the excerpt does not disclose the earnings catalyst.
Earnings call details multiple 2026 demand and reimbursement headwinds (referral inflow execution gap, TDAPA, ACA subsidy expiration) plus offsetting 5008X conversion progress and buyback.
Operational volume deterioration in the U.S. is a direct negative fundamental signal.
alphai scores every news story that mentions FMS with an AI model for sentiment and relevance, and aggregates insider trades from Fresenius Medical Care AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
Fresenius Medical Care AG reported interim results of its first tranche share buyback. From Aug 10 to Aug 14, 2026, it bought back 722,500 shares at weighted average prices around EUR 41.06 to EUR 42.36, totaling EUR 30.65m. A total of 5,151,274 shares have been acquired so far, via a commissioned credit institution.
2 min readFresenius Medical Care (FMS) reported Q2 2026 revenue of EUR 4,861 million, up 5% organically, and adjusted operating income of EUR 569 million (+23% at constant currency). Adjusted basic EPS was EUR 1.13 (+28% constant currency). Management reaffirmed broadly flat 2026 revenue and operating income growth, citing U.S. referral execution issues and China regulatory headwinds.
6 min readGermany’s DAX rose modestly in Thursday morning trading, reaching 26,210.50 before easing to 26,169.49 (+0.12%). Deutsche Telekom gained about 6% on Q2 operating profit of €6.863bn and a larger 2026 buyback. Merck rose 1.5% after upgrading full-year guidance. Other moves included Henkel (+4.3%) and Siemens (-6%).
4 min readFresenius Medical Care reported Q2 2026 operating income up 23%, helped by EUR 67m FME25+ transformation savings. U.S. same-market treatment growth fell 0.9% due to referral capture and confirmation execution issues. The company exited about 100 underperforming clinics, revised 2026 outlook including a EUR 50m TDAPA headwind and EUR 150m to EUR 200m value-based care revenue decline, and launched a second EUR 1bn buyback.
7 min readEuropean stocks closed higher on Tuesday. The pan-European Stoxx 600 rose 0.73%, with DAX up 0.77% and CAC 40 up 0.61%. Brent crude fell nearly 6% to $78.70. Company moves included Travis Perkins +18.5% on strong interim results, Smith & Nephew -6% after cutting its forecast, and Zalando -13.4% after lowering its 2026 outlook. HSBC reported $14.626B net income and announced a share buyback.
6 min readFresenius Medical Care (NYSE:FMS) reported Q2 call highlights, including clinic closures of about 100 underperforming sites and rollout of high-volume hemodiafiltration. The company said U.S. same-market treatment growth for 2026 should stay around Q2 levels due to lower referrals. Care Delivery operating income rose 45% and FCF was EUR 625 million. It expects TDAPA to be a EUR 50 million full-year headwind and is buying back shares under a EUR 1 billion program.
6 min readGerman stocks rose for a fourth straight session, with the DAX hitting a record 26,267.62 before easing to 26,154.75 (+0.45%). Gains were supported by upbeat earnings and a U.S. ISM manufacturing PMI jump to 55.6. Bayer, Rheinmetall, and Infineon rose. Zalando cut its 2026 outlook, Fresenius Medical Care fell, and Lufthansa dropped on lower profit guidance.
4 min readFresenius Medical Care shares fell 8.0% to about €41.29 after its Q2 2026 results. The company reported operating income excluding special items of €569 million and revenue of €4.861 billion, both above consensus, but U.S. same-market treatment volumes declined about 0.9% YoY. Analysts cited unchanged guidance and volume risk, reiterating lower price targets.
5 min readFresenius Medical Care reported Q2 2026 organic revenue growth of 5% and operating income up 23% to a margin of 11.7%. Reported operating income rose 10%, while net income fell 3%. EPS increased 28% supported by share buybacks. The company said 227 U.S. clinics converted to its 5008X CAREsystem with 600,000+ treatments and reaffirmed its FY 2026 outlook.
5 min readFresenius Medical Care AG appointed Cassie McLean to its Management Board effective Aug. 1, 2026. She becomes CEO of the Care Delivery segment, succeeding Craig Cordola. McLean joined in Aug. 2025 as President of Fresenius Kidney Care and will oversee global clinics, including U.S. and international. Fresenius said the move supports its Care Delivery strategy and mid-term financial goals.
2 min read
